Aspect Biosystems

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company's proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect's bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.

Research Vancouver, Canada ~124 employees Private · Series A

Work at Aspect Biosystems in HR or recruiting? Claim this page

Employees
124
0% in the 3 months to Sep 2026
Revenue / employee
$52.4K
Revenue ~$6.5M
Total funding
$23.7M
Last round Series A, Jan 2020
12-month attrition
16.5%
Tech: 37.1%
H1B sponsor
NA

Headcount trend

Aspect Biosystems went from 96 employees in Oct 2024 to 124 in Sep 2026. Apr to Sep 2026: 18 people joined, 8 left.

Funding rounds

Total funding$23.7M
Funding rounds5
Investors8
DateRoundMoney raisedNo.Investors
Jan 2020Series A$20M4
Nov 2018Funding$2.7M––
May 2018Venture$1M1
Sep 2017Funding–4
Jul 2017Angel–1

Org structure

Headcount by department

Other69
Operations23
Engineering18
Finance7
HR2
Sales2
Marketing2
Design1

Aspect Biosystems FAQ

How many employees does Aspect Biosystems have?

Aspect Biosystems has about 124 employees, unchanged over the 3 months to Sep 2026.

What is Aspect Biosystems's revenue per employee?

Aspect Biosystems makes about $52K in revenue per employee, based on $6.5M annual revenue and 124 employees.

How much funding has Aspect Biosystems raised?

Aspect Biosystems has raised $23.7M in total funding; its latest round was Series A in Jan 2020.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.